CHEMOTHERAPY FOR HIV-ASSOCIATED KAPOSI’S SARCOMA

N. Busakhalala
What is it?

A malignant, multifocal systemic disease that originates from the vascular endothelium.
Clinical forms

Classic

Immunosuppression

Endemic African

Epidemic HIV-associated
Etiology

Infection with human herpes virus-8 (HHV-8), which is transmitted sexually or via blood or saliva. (Andreoni et al. 2002).
HAART decreased KS

90% in the Department of Dermatovenereology at Frankfurt Univ Hosp, and the clinical course of disease has improved significantly
Signs, symptoms and diagnosis

In contrast to the classical KS found in older men, in whom the tumors usually occur on the lower legs and feet, HIV-associated KS does not have a preferential pattern of localization.
Staging
HISTOLOGY?

HHV-8, can be detected in tumor tissue by PCR. Antibodies are often detected months before the clinical manifestation of the tumor.
Neutralizing antibodies

Are protective (Kimball 2004)

In patients with KS the titres of neutralizing antibodies are low.
Treatment

If the HIV viral load can be reduced (ideally below the level of detection) and immune reconstitution is achieved with increase in CD4 cell count, KS resolves except certain PIs: Indinavir, Saquinavir, and Ritonavir.
CHEMOTHERAPY

Liposomal anthracyclines are first line.
Paclitaxel or (ABV regimen) are second
<table>
<thead>
<tr>
<th>RESPONSE</th>
<th>COMPLETE</th>
<th>PARTIAL</th>
<th>NONE</th>
<th>ID</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>8</td>
<td>17</td>
<td>17</td>
<td>28</td>
<td>70</td>
</tr>
<tr>
<td>Female</td>
<td>3</td>
<td>12</td>
<td>4</td>
<td>9</td>
<td>28</td>
</tr>
<tr>
<td>Total</td>
<td>11</td>
<td>29</td>
<td>21</td>
<td>37</td>
<td>98</td>
</tr>
</tbody>
</table>
CD4 CELLS

- Males mean 222/μl
- Females mean 160/μl
- Does male gender predispose to KS?
<table>
<thead>
<tr>
<th>RESPONSE</th>
<th>COMPLETE</th>
<th>PARTIAL</th>
<th>NONE</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE(YRS)</td>
<td>39 (27-60)</td>
<td>35 (24-48)</td>
<td>35 (28-52)</td>
<td>38 (24-57)</td>
</tr>
<tr>
<td>CD4</td>
<td>261 (35-581)</td>
<td>307 (35-573)</td>
<td><strong>186</strong> (6-513)</td>
<td>142 (6-531)</td>
</tr>
</tbody>
</table>
AGE

- No association here.

- CD4 CELL COUNT BELOW 200/µl, maybe.
## Location

<table>
<thead>
<tr>
<th>RESPONSE</th>
<th>COMPLETE</th>
<th>PARTIAL</th>
<th>NONE</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOWER LIMB</td>
<td>4</td>
<td>6</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>PALATE</td>
<td>3</td>
<td></td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>GENERALISED</td>
<td>4</td>
<td>23</td>
<td>10</td>
<td>26</td>
</tr>
</tbody>
</table>
## Side Effects and Courses

<table>
<thead>
<tr>
<th>RESPONSE</th>
<th>COMPLETE</th>
<th>PARTIAL</th>
<th>NONE</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEUTROPENIA</td>
<td>0</td>
<td>8</td>
<td>16</td>
<td>11</td>
</tr>
<tr>
<td>NUMBER OF COURSES</td>
<td>6 (4-8)</td>
<td>6 (4-10)</td>
<td>7 (3-9)</td>
<td>2 (1-5)</td>
</tr>
</tbody>
</table>
Predicting outcome

- NEUTROPENIA
- CD4 CELL COUNT >200/μl
ACKNOWLEDGEMENTS

- The oncology team
- Ampath
- Eldochem
- The patients
Thank you all for listening.